<DOC>
	<DOCNO>NCT01676285</DOCNO>
	<brief_summary>Cirrhotic cardiomyopathy define chronic cardiac dysfunction patient cirrhosis . It suspect specific cardiac dysfunction contributes onset complication liver disease . The purpose prospective , randomized trial determine whether metoprolol succinate revert cardiac dysfunction secondary cirrhosis ( cirrhotic cardiomyopathy ) , prevent complication ( renal dysfunction , mortality ) . A total 100 patient cirrhotic cardiomyopathy randomize ( Group R ) receive metoprolol succinate placebo ; 25 patient without cirrhotic cardiomyopathy ( Group F ) follow without medication . All patient evaluate begin six month . The assessment protocol include clinical evaluation , electrocardiogram , echocardiogram , laboratory analysis life quality questionaire . The end point cardiac remodeling , electrophysiologic change , sympathetic activity , laboratory issue change , renal function , quality life , mortality .</brief_summary>
	<brief_title>Metoprolol Succinate Cardiac Remodeling Related Cirrhosis</brief_title>
	<detailed_description>Cirrhotic cardiomyopathy ( CMC ) define chronic cardiac dysfunction patient cirrhosis . Moreover , characterize abnormal blunt response pathological pharmacological stress absence associate cardiac disease . The diagnostic criterion : baseline increase cardiac output , attenuate myocardial contractile response stress , diastolic dysfunction , electrophysiological repolarization abnormality . It suspect cardiac dysfunction cirrhosis contribute onset complication liver disease . We investigate effect metoprolol succinate reversal cardiac dysfunction prevention complication cirrhosis patient cirrhotic cardiomyopathy . Furthermore , want study influence presence CMC evolution cirrhotic patient . The study prospective , randomize , double-blind , placebo-controlled . The sample consist 125 patient age 18 60 year old diagnose severe liver cirrhosis ( Child B C MELD score 10 ) cirrhotic cardiomyopathy . Of , 100 patient cirrhotic cardiomyopathy randomize two group : group R1 ( metoprolol succinate ) group R2 ( placebo ) . Group F consist cirrhotic patient without cardiomyopathy receive medication . Patients evaluate clinical examination , rest electrocardiogram , 24-hour Holter , stress echocardiography laboratory ( brain natriuretic peptide ( BNP ) , catecholamine , plasma renin activity , troponin ) inclusion six month . The end point : 1 ) Reversal cardiac dysfunction patient cirrhotic cardiomyopathy , 2 ) Development hepatorenal syndrome , 3 ) Reversal electrophysiologic abnormality , 4 ) Changes laboratory test , 5 ) Mortality .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>18 year old . must sign write informed consent . nonalcoholic cirrhosis . Betablockers intolerance ; Diagnosis cardiomyopathy Chronicle renal disease ( Creatinine &gt; 2.5 ) Heavy alcohol intake history Presence disease possible cardiac implication ( infiltrative storage disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>cirrhotic cardiomyopathy</keyword>
	<keyword>cardiac remodeling</keyword>
	<keyword>cardiomyopathy</keyword>
	<keyword>metoprolol succinate</keyword>
	<keyword>betablockers</keyword>
</DOC>